Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DIOVAN HCT vs ALDORIL D50
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Valsartan is an angiotensin II receptor blocker (ARB) that selectively blocks the binding of angiotensin II to the AT1 receptor, causing vasodilation and reduced aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride cotransporter in the distal convoluted tubule, increasing excretion of sodium and water.
Aldoril D50 is a combination of methyldopa and hydrochlorothiazide. Methyldopa is a centrally-acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume and further lowering blood pressure.
Hypertension (FDA-approved),Heart failure (off-label, valsartan component),Post-myocardial infarction (off-label, valsartan component)
Hypertension (first-line or second-line therapy),Hypertensive urgency (off-label)
One tablet orally once daily. Available strengths: 80 mg/12.5 mg, 160 mg/12.5 mg, 160 mg/25 mg, 320 mg/12.5 mg, 320 mg/25 mg. Titrate to blood pressure response; maximum dose 320 mg/25 mg daily.
1 tablet (hydrochlorothiazide 25 mg + methyldopa 250 mg) orally twice daily; maximum dose: 2 tablets (50 mg + 500 mg) twice daily.
Valsartan: 6 hours; hydrochlorothiazide: 6–15 hours (mean 9.6 hours). Clinical context: allows once-daily dosing; half-life prolonged in renal impairment.
3–6 hours (terminal elimination half-life); clinical context: requires twice-daily dosing for sustained blood pressure control; prolonged in renal impairment.
Valsartan is primarily metabolized by CYP2C9 (minor) and eliminated unchanged in bile and urine. Hydrochlorothiazide is not extensively metabolized and is excreted unchanged in urine.
Methyldopa is extensively metabolized in the liver via conjugation and O-methylation, with involvement of catechol-O-methyltransferase (COMT). Hydrochlorothiazide is not extensively metabolized; it is eliminated largely unchanged by the kidneys.
Valsartan: primarily biliary (83%) and renal (13%) as unchanged drug; hydrochlorothiazide: renal (≥95%) as unchanged drug.
Renal: 50% as unchanged drug and 20% as metabolites; biliary/fecal: ~25% (as metabolites); total renal clearance accounts for ~70% of elimination.
Valsartan: 94–97% (primarily albumin); hydrochlorothiazide: 68% (albumin).
~20% bound to albumin; minimal binding to other plasma proteins.
Valsartan: 17 L (≈0.24 L/kg for 70 kg); hydrochlorothiazide: 3.6–7.8 L/kg (≈0.5–1.1 L/kg). Clinical meaning: Valsartan distributes mainly in plasma; HCTZ widely distributed into tissues.
0.2–0.3 L/kg (moderately low Vd, indicating limited extravascular distribution and predominantly plasma water distribution).
Valsartan: 25% (oral, with food reduces absorption by 40%); hydrochlorothiazide: 65–75% (oral).
Oral: 30–40% (due to extensive first-pass metabolism); IV: 100%.
Contraindicated in anuria. For GFR 30-60 m L/min, use cautiously; consider lower starting doses. GFR <30 m L/min: not recommended due to thiazide component.
Contraindicated if GFR < 30 m L/min; for GFR 30-50 m L/min: reduce dose and monitor electrolytes.
Child-Pugh A: no adjustment. Child-Pugh B: use caution; valsartan exposure increases significantly. Child-Pugh C: avoid use.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50% and monitor; Class C: contraindicated.
Not approved for pediatric patients; safety and efficacy not established.
Not recommended; inadequate safety data.
No initial dose adjustment required, but consider lower starting doses due to greater sensitivity to antihypertensive effects; monitor renal function and electrolytes.
Start with 1 tablet (hydrochlorothiazide 12.5 mg + methyldopa 125 mg) once daily; increase slowly; monitor for hypotension and electrolyte imbalance.
None.
None
Fetal toxicity: avoid use during pregnancy; can cause oligohydramnios and fetal renal dysfunction.,Hypotension in volume-depleted patients.,Electrolyte imbalances (e.g., hypokalemia, hyponatremia) due to thiazide component.,Renal impairment: monitor renal function; may exacerbate in bilateral renal artery stenosis.,Acute angle-closure glaucoma (thiazide component).,Sulfonamide allergy (cross-reactivity with thiazide).,Exacerbation of lupus erythematosus.
Sedation and drowsiness common; avoid driving or hazardous activities. Risk of Coombs-positive hemolytic anemia with methyldopa (discontinue if anemia develops). Hepatotoxicity and liver function abnormalities (discontinue if jaundice occurs). Orthostatic hypotension; caution in volume-depleted patients. Electrolyte imbalances (particularly hypokalemia, hyponatremia) with hydrochlorothiazide; monitor serum electrolytes. Sulfonamide cross-sensitivity possible. Exacerbation of systemic lupus erythematosus. Avoid abrupt withdrawal of methyldopa (may cause rebound hypertension).
Anuria,Hypersensitivity to valsartan, hydrochlorothiazide, or sulfonamide-derived drugs,Pregnancy (second and third trimesters),Severe hepatic impairment (Child-Pugh class C),Concomitant use with aliskiren in patients with diabetes mellitus or renal impairment (GFR <60 m L/min)
Active hepatic disease (cirrhosis, hepatitis) associated with methyldopa therapy; previous methyldopa-induced liver disorders. Anuria or hypersensitivity to thiazide diuretics or sulfonamide-derived drugs. Concomitant use with MAO inhibitors. Severe renal impairment (creatinine clearance <30 m L/min) or electrolyte depletion due to hydrochlorothiazide. Concurrent lithium therapy (risk of lithium toxicity).
Avoid grapefruit juice as it may alter drug metabolism. Limit high-potassium foods (e.g., bananas, oranges, potatoes, spinach) if potassium levels rise. Reduce sodium intake (less than 2 g/day) to enhance antihypertensive effect. Avoid excessive alcohol consumption. Maintain adequate fluid intake to prevent dehydration.
Avoid potassium supplements or salt substitutes containing potassium without consulting doctor. Limit alcohol intake. Avoid excessive grapefruit juice. Maintain adequate potassium intake through diet to prevent hypokalemia.
First trimester: Potential risk based on mechanism (angiotensin II receptor blockade and thiazide diuretic); second and third trimesters: Known fetal toxicity including oligohydramnios, fetal renal dysfunction, skull ossification defects, and neonatal hypotension; avoid in pregnancy, especially after 20 weeks gestation.
Hydrochlorothiazide (HCTZ) is Pregnancy Category B in first trimester and Category D in second/third trimesters. Methyldopa (M) is Category B. HCTZ use in second/third trimester may cause fetal/neonatal effects including electrolyte disturbances, jaundice, thrombocytopenia, and possible fetal growth restriction. Methyldopa has not shown teratogenicity. Aldoril D50 (M 500mg/HCTZ 50mg) is not recommended during pregnancy, especially after first trimester.
The active metabolites hydrochlorothiazide is excreted in low amounts in breast milk; low M/P ratio of approximately 0.25; valsartan excretion unknown; because of potential adverse effects on the nursing infant, especially renal effects, use is not recommended; alternative therapies are preferred.
Both methyldopa and HCTZ are excreted in breast milk. Methyldopa M/P ratio approximately 1.0; HCTZ M/P ratio variable, small amounts. Use during breastfeeding may suppress lactation due to HCTZ diuretic effect. Monitor infant for signs of hypotension, electrolyte imbalance. Caution recommended; use only if clearly needed.
Dose adjustments are not applicable as DIOVAN HCT is contraindicated in pregnancy; exposure should be avoided; if required, consider switching to an alternative antihypertensive with a safer profile during pregnancy.
Pregnancy-induced increase in plasma volume may reduce effectiveness of HCTZ, requiring dose adjustment. Methyldopa pharmacokinetics not significantly altered; however, increased clearance in pregnancy may require higher doses. In preeclampsia, dose adjustments may be needed. Avoid HCTZ in pregnancy if possible.
Diovan HCT combines valsartan (ARB) and hydrochlorothiazide (thiazide diuretic). Monitor renal function, electrolytes (especially potassium and sodium), and blood pressure. Avoid use in pregnancy; contraindicated in anuria and severe renal impairment. Use caution in patients with pre-existing electrolyte imbalances, diabetes, or history of gout. May cause hyperkalemia with valsartan and hypokalemia with HCTZ; net effect requires monitoring. Onset of action within 2 hours, peak effect at 4-6 hours. Not recommended for initial therapy; titrate from individual components.
ALDORIL D50 combines methyldopa and hydrochlorothiazide. Monitor for orthostatic hypotension, especially in volume-depleted patients. May cause positive Coombs test, hemolytic anemia, and lupus-like syndrome. Avoid in pheochromocytoma. Use caution in hepatic disease.
Take exactly as prescribed, usually once daily. Do not skip doses.,Avoid potassium supplements or salt substitutes without doctor approval.,Report symptoms of electrolyte imbalance: muscle cramps, weakness, irregular heartbeat, excessive thirst.,May cause dizziness or lightheadedness; avoid driving until you know how it affects you.,This medication can make you urinate more frequently; take in the morning to minimize nighttime urination.,Avoid alcohol, which can increase dizziness and blood pressure lowering effects.,Notify your doctor if you become pregnant or plan to become pregnant; this drug can harm the fetus.,Stay hydrated, especially in hot weather or during exercise, to prevent dehydration.,Tell your doctor about all other medications, especially NSAIDs, lithium, and other blood pressure drugs.,Do not stop taking without consulting your doctor; sudden discontinuation may worsen blood pressure.
Take exactly as prescribed; do not skip doses or double up.,May cause dizziness or drowsiness; avoid driving until you know how it affects you.,Report unexplained fever, jaundice, or dark urine immediately.,Avoid sudden discontinuation; may cause rapid increase in blood pressure.,Stay hydrated but do not overhydrate; monitor for signs of electrolyte imbalance.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DIOVAN HCT vs ALDORIL D50, answered by our medical review team.
DIOVAN HCT is a Antihypertensive Combination that works by Valsartan is an angiotensin II receptor blocker (ARB) that selectively blocks the binding of angiotensin II to the AT1 receptor, causing vasodilation and reduced aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride cotransporter in the distal convoluted tubule, increasing excretion of sodium and water.. ALDORIL D50 is a Antihypertensive Combination that works by Aldoril D50 is a combination of methyldopa and hydrochlorothiazide. Methyldopa is a centrally-acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume and further lowering blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DIOVAN HCT and ALDORIL D50 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DIOVAN HCT is: One tablet orally once daily. Available strengths: 80 mg/12.5 mg, 160 mg/12.5 mg, 160 mg/25 mg, 320 mg/12.5 mg, 320 mg/25 mg. Titrate to blood pressure response; maximum dose 320 mg/25 mg daily.. The standard adult dose of ALDORIL D50 is: 1 tablet (hydrochlorothiazide 25 mg + methyldopa 250 mg) orally twice daily; maximum dose: 2 tablets (50 mg + 500 mg) twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DIOVAN HCT and ALDORIL D50 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DIOVAN HCT is classified as Category C. First trimester: Potential risk based on mechanism (angiotensin II receptor blockade and thiazide diuretic); second and third trimesters: Known fetal toxicity including oligohydram. ALDORIL D50 is classified as Category C. Hydrochlorothiazide (HCTZ) is Pregnancy Category B in first trimester and Category D in second/third trimesters. Methyldopa (M) is Category B. HCTZ use in second/third trimester ma. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.